Eli Lilly and Company
Mega Cap · Healthcare · Drug Manufacturers - General
$1,180.20−$28.80 (-2.38%)
Eli Lilly and Company
Mega Cap · Healthcare · Drug Manufacturers - General
$1,180.20−$28.80 (-2.38%)
Stock analysis
Stock Fundamentals & Key Indicators
52-week range
Low$623.78
High$1,249.45
Today $1,180.20
RSI (14)
47.3Neutral
03070100
Overall score
77/100
See the full financial picture
Open the five-year record, valuation checks and Wall Street view behind these scores.
- ✓5 years of revenue, profit and cash flow
- ✓Valuation and balance-sheet checks
- ✓Business and geographic mix
- ✓Analyst targets and recommendation trend
Free for 3 days, then $9/mo. Cancel anytime.
Analyst Rating and Sentiment
Analyst price targets
Lowest
$850
Current price
$1,180.2
Median target
$1,344
Highest
$1,600
LowHigh
Operating Record
Revenue
What's working
- ROIC: Money put back into the business keeps coming back out as profit, a hallmark of a durable moat.
- ROE: Shareholder capital is compounding at a rate worth paying attention to.
What to watch
- Debt exceeds cash by $46.0B, increasing balance-sheet pressure, a warning sign.
- Forward P/E: The price already assumes strong earnings growth that still has to show up.
What the market charges
Forward P/E
Needs attention · 48% above avg
28.96x
Price / sales
Rich · Priced well above what its revenue alone supports
13.27x
Price / FCF
Rich · Priced far above what its cash flow currently supports
58.10x
EV / EBITDA
Rich · Operating earnings don't yet support this price
30.84x
How efficiently it compounds
ROIC
Strong · Comfortably clears the bar for efficient capital use
42.2%
ROE
Favorable · 107.6% - strong capital efficiency
102.3%
Debt / equity
Needs attention · Unfavorable
1.62x
Current ratio
Reasonable · Just enough on hand to cover near-term bills
1.35x
Peer Comparison
| Company | Mkt cap | P/E | Rev growth | Score |
|---|---|---|---|---|
| $1.12T | 40.3 | +49.6% | 77 |
 | $11.12B | 21.1 | +19.7% | 78 |
 | $4.58B | 13.8 | +13.6% | 77 |
 | $31.98B | 33.5 | +15.5% | 77 |
 | $71.46B | 20.0 | +13.5% | 73 |
What is moving LLY
News
- 1d ago · Eli Lilly and Company via Yahoo Finance
Eli Lilly (LLY) Steps Up Legal Fight Over Illegal Retatrutide Sales
Mixed 
1d ago · Eli Lilly and Company via Nasdaq
Eli Lilly Just Scored Europe's First Weight Loss Pill Approval -- and the Growth Story Keeps Getting Bigger
Bullish- 1d ago · Eli Lilly and Company via Yahoo Finance
Eli Lilly Stock Nears Buy Point After Earnings-Fueled Gains
Bullish - 1d ago · Eli Lilly and Company via Yahoo Finance
5 Revealing Analyst Questions From Eli Lilly’s Q2 Earnings Call
Bullish - 2d ago · Eli Lilly and Company via Yahoo Finance
Novo Nordisk Stock Slips as Pill Strategy Reframes Obesity Race
Bearish - 2d ago · Eli Lilly and Company via Yahoo Finance
Eli Lilly's GLP-1 Pricing Problem Is Actually a Growth Opportunity
Bullish - 2d ago · Eli Lilly and Company via Nasdaq
Eli Lilly's GLP-1 Pricing Problem Is Actually a Growth Opportunity
Bullish